Trevi Therapeutics (TRVI) Net Cash Flow (2018 - 2026)

Trevi Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $498000.0 for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 103.38% year-over-year to $498000.0 in Q1 2026; TTM through Mar 2026 was $38000.0, a 99.32% decrease from a year earlier, with the FY2025 full-year figure at -$15.2 million, down 993.12% from the prior year.
• Net Cash Flow improved to $498000.0 in Q1 2026 per TRVI's latest filing, from -$38.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $97.7 million in Q2 2025 and bottomed at -$60.2 million in Q3 2025.
• The 5-year median for Net Cash Flow is $498000.0 (2026), against an average of $2.2 million.
• Biggest YoY gain for Net Cash Flow was 11619.34% in 2025; the steepest drop was 2048.49% in 2025.
• Year by year, Net Cash Flow stood at -$54.0 million in 2022, then jumped by 111.91% to $6.4 million in 2023, then soared by 180.55% to $18.0 million in 2024, then plunged by 310.34% to -$38.0 million in 2025, then jumped by 101.31% to $498000.0 in 2026.
• Per Business Quant, the three latest TRVI Net Cash Flow figures stand at $498000.0 (Q1 2026), -$38.0 million (Q4 2025), and -$60.2 million (Q3 2025).